Net income
-36.3 million USD
2025-07-01 – 2026-06-30
Fundies. English
AN2 THERAPEUTICS, INC.
EDGAR24 filing records in this dataset, filed from 2022-03-04 to 2026-08-11. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 44.3 million USD Source
Exact value
44300000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 36.3 million shares Source
Exact value
36308669 shares
Reported share-count change
32.63% · 8.93 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-11.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 5 of 11 periods available· newest 2025-12-31
- Net income: 5 of 11 periods available· newest 2025-12-31
- Operating cash flow: 5 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 5 of 11 periods available· newest 2025-12-31
- Total liabilities: 5 of 11 periods available· newest 2025-12-31
- Current assets: 5 of 11 periods available· newest 2025-12-31
- Current liabilities: 5 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 5 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 5 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
+USD 16.15 millionPrior period
−USD 51.32 million
–
Current period
−USD 35.17 million
–
Exact inputs and evidence
-35174000 − -51321000 = 16147000 USD
-51321000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-35174000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 19.42 millionPrior period
−USD 49.26 million
–
Current period
−USD 29.83 million
–
Exact inputs and evidence
-29834000 − -49257000 = 19423000 USD
-49257000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-29834000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2021 2021-01-01 – 2021-12-31 | −USD 21.54 million Exact valueExact value: -21543000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 20.48 million Exact valueExact value: -20484000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | −USD 40.96 million Exact valueExact value: -40956000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 33.46 million Exact valueExact value: -33462000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −USD 64.73 million Exact valueExact value: -64732000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 53.29 million Exact valueExact value: -53288000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 51.32 million Exact valueExact value: -51321000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 49.26 million Exact valueExact value: -49257000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 35.17 million Exact valueExact value: -35174000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 29.83 million Exact valueExact value: -29834000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
24 filings · 1,012 latest values · 1,012 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001880438, 1880438, ANTX, edgar:1880438
Also known as AN2 THERAPEUTICS, INC., AN2 Therapeutics, Inc.